Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.

Trial Details

NCT ID
NCT05950945
Phase
PHASE3
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Trastuzumab Deruxtecan
Locations (sample)
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Summit, New Jersey, United States|40.71562,-74.36468
  • North Sydney, New South Wales, Australia|-33.839,151.2072
  • East Bentleigh, Victoria, Australia

Key Eligibility Criteria

  • Sign and date the main informed consent form
  • Must agree to provide a newly obtained or archival baseline biopsy from primary and/or metastatic lesion.
  • Pathologically documented Breast Cancer (BC) tumor
  • Is unresectable and/or metastatic.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →